What is Oviva?
Founded in 2014 and headquartered in Altendorf, Switzerland, Oviva leverages technology to assist individuals managing chronic conditions such as obesity, diabetes, and food allergies. The company provides personalized medical nutritional therapy through a secure smartphone application, offering both in-person and remote support from professional dietitians. Oviva's innovative approach integrates digital tools with expert guidance, aiming to improve patient health outcomes and accessibility to care. The company's operations span across multiple European markets, positioning it as a key player in the digital therapeutics landscape.
How much funding has Oviva raised?
Oviva has raised a total of $313.8M across 5 funding rounds:
Seed
$800K
Series A
$12M
Series B
$21M
Series C
$80M
Series D
$200M
Seed (2016): $800K, investors not publicly disclosed
Series A (2017): $12M led by F-Prime Capital Partners, Walking Ventures, Albion Capital Group LLP, Partech Ventures, and Eight Roads Ventures
Series B (2020): $21M supported by Partech, MTIP, Earlybird, F-Prime Capital, Albion Capital Group, and Eight Roads Ventures
Series C (2021): $80M featuring Mtip, Albion Capital Group, F-Prime Capital Partners, Temasek, Sofina, Earlybird, and Eight Roads Ventures
Series D (2026): $200M backed by AP Moller Group, Planet First Partners, Kinnevik, Temasek, Lunate, Sofina, Norrsken Vc, and EGS Beteiligungen
Key Investors in Oviva
F-Prime Capital Partners
F-Prime Capital Partners is a venture capital firm specializing in healthcare and technology investments, known for supporting innovative companies from their early stages through growth.
Albion Capital Group LLP
AlbionVC, the technology investment arm of Albion Capital Group, focuses on B2B software and technology-enabled services, providing capital and scale-up expertise to high-growth companies.
Partech Ventures
Partech is a global investment firm supporting entrepreneurs across seed, venture, and growth stages with capital and operational experience in a wide range of technologies and businesses.
What's next for Oviva?
With its latest major strategic investment, Oviva is poised for accelerated expansion and further development of its digital health platform. The substantial capital infusion, indicated by the $313.8M and $200M figures, suggests a scaling phase, likely enabling Oviva to enhance its service offerings, broaden its market reach, and potentially explore new therapeutic areas. This funding will be critical in solidifying its position as a leader in digital health solutions for chronic disease management.
See full Oviva company page
